The closing price of Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) was $0.72 for the day, down -2.82% from the previous closing price of $0.74. In other words, the price has decreased by -$0.0209 from its previous closing price. On the day, 598885 shares were traded.
Ratios:
Our analysis of BCLI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.24 and its Current Ratio is at 0.24.
Maxim Group reiterated its Buy rating for the stock on December 19, 2016, while the target price for the stock was revised from $5 to $6.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 01 ’23 when Lindborg Stacy bought 11,500 shares for $1.77 per share. The transaction valued at 20,402 led to the insider holds 181,500 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCLI now has a Market Capitalization of 34.78M and an Enterprise Value of 36.25M.
Stock Price History:
Over the past 52 weeks, BCLI has reached a high of $3.43, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 0.3972, while the 200-Day Moving Average is calculated to be 0.7782.
Shares Statistics:
BCLI traded an average of 970.48K shares per day over the past three months and 1.89M shares per day over the past ten days. A total of 60.49M shares are outstanding, with a floating share count of 40.23M. Insiders hold about 17.86% of the company’s shares, while institutions hold 8.09% stake in the company. Shares short for BCLI as of Mar 15, 2024 were 850.26k with a Short Ratio of 0.88, compared to 1.23M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.74% and a Short% of Float of 1.82%.
Earnings Estimates
The firm’s stock currently is rated by 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.19. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.7 and -$0.7 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is -$0.47, with 1 analysts recommending between -$0.47 and -$0.47.
